Key facts
- This page summarizes Filip Dubovsky's Form 4 filing for NOVAVAX INC (NVAX).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 12 Mar 2024, 20:46.
Filip Dubovsky - 10 Mar 2024 Form 4 Insider Report for NOVAVAX INC (NVAX)
- Reporting relationship
- President, R&D
- Issuer ticker
- NVAX
- Reported as of
- 10 Mar 2024
- Net transaction value
- -$14,154
- SEC form
- 4
- Accepted by SEC
- 12 Mar 2024, 20:46:00 UTC
- Prior SEC filing
- 11 Mar 2024
- Next SEC filing
- 15 May 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mark J. Casey, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Filip Dubovsky filed Form 4 for NOVAVAX INC (NVAX) on 12 Mar 2024.
Change
- Previous filing in this sequence was filed on 11 Mar 2024.
- Current net transaction value: -$14,154.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NVAX
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +5,376
- Change %
- +8.4%
- Price
- Shares after
- 69,210
- Date
- 10 Mar 2024
- Ownership
- Direct
- Footnotes
- F1
NVAX
transaction
Common Stock
Tax liability
- Transaction value
- $14,154
- Shares
- -2,597
- Change %
- -3.8%
- Price
- $5.45
- Shares after
- 66,613
- Date
- 10 Mar 2024
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NVAX
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -5,376
- Change %
- -50%
- Price
- $0.000000
- Shares after
- 5,376
- Date
- 10 Mar 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,376
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.
Footnote F2
The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the March 10, 2022 grant date, in each case subject to continued employment through such vesting date